We don't know if the hype is over around MRNA.
It has probably finished its 5-wave impulse and will need to settle down in correction.
There is support zone in the range 87-103 formed by previous price highs and some Fibo levels as seen on the chart.
From the fundamental point of view we could compare Moderna with some other biotechs: AMGN, GILD, VRTX, REGN, ILMN, BIIB.
Their P/S ratios (Price to Sale) are in the range from 3.50 to 14.50.
Big names like GSK, PFE, MRK make 5-7bn in all vaccine sales per year.
If MRNA makes $2bn in sales, at P/S=15 their Market Cap should be around $30bn --> $77 per share.
It has probably finished its 5-wave impulse and will need to settle down in correction.
There is support zone in the range 87-103 formed by previous price highs and some Fibo levels as seen on the chart.
From the fundamental point of view we could compare Moderna with some other biotechs: AMGN, GILD, VRTX, REGN, ILMN, BIIB.
Their P/S ratios (Price to Sale) are in the range from 3.50 to 14.50.
Big names like GSK, PFE, MRK make 5-7bn in all vaccine sales per year.
If MRNA makes $2bn in sales, at P/S=15 their Market Cap should be around $30bn --> $77 per share.
